---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-089871"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:45:31.141121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics Q4 net loss $23M; cash $152.4M; FDA clears TSC-102 INDs; plans Phase 3 trial Q2 2026

## Summary
- Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.
- Cash and equivalents $152.4M as of Dec 31, 2025; funds operations into H2 2027.
- FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 for heme malignancies post-HCT.
- Enrollment completed in Cohort C of ALLOHA heme trial with commercial-ready manufacturing; initial data due Q2 2026.
- Discontinued solid tumor PLEXI-T trial; advancing in vivo TCR-T engineering and autoimmunity programs.

## SEC filing metadata
- accession: 0001193125-26-089871
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/0001193125-26-089871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/tcrx-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-089871
- JSON: https://secwatch.observer/filing/0001193125-26-089871.json
- Plain text: https://secwatch.observer/filing/0001193125-26-089871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.